(H4Z3) HSBC MSCI Emerging Markets - Ratings and Ratios
Stocks, Asia, China, Taiwan, India
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 15.1% |
| Value at Risk 5%th | 23.8% |
| Relative Tail Risk | -3.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 6.80 |
| CAGR/Max DD | 0.52 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.631 |
| Beta | 0.204 |
| Beta Downside | 0.462 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.86% |
| Mean DD | 4.12% |
| Median DD | 3.95% |
Description: H4Z3 HSBC MSCI Emerging Markets November 09, 2025
The HSBC MSCI Emerging Markets UCITS ETF (USD Acc) – ticker H4Z3 on XETRA – tracks the Morningstar Emerging Markets Total Market Index (NR USD). It is a Germany-domiciled, globally diversified equity ETF that provides exposure to large-, mid- and small-cap stocks across 26 emerging economies, with a focus on USD-denominated returns while accumulating dividends.
Key quantitative points (as of the latest public data) include an expense ratio of 0.15 % and total assets under management of roughly €4.5 bn, placing it among the larger EM equity ETFs. The fund’s top sector weights are financials (≈ 23 %), technology (≈ 15 %) and consumer discretionary (≈ 12 %), reflecting the continued growth of banking and digital services in markets such as China, India and Brazil. Recent macro drivers – a projected 4-5 % real GDP growth in emerging markets for 2025 and a gradual easing of commodity price volatility – underpin the long-term upside potential of the underlying index.
If you want a deeper, data-driven assessment of how this ETF’s risk-adjusted performance stacks up against peers and fits into a diversified emerging-market strategy, consider exploring the analysis on ValueRay.
What is the price of H4Z3 shares?
Over the past week, the price has changed by -2.17%, over one month by -4.03%, over three months by +3.52% and over the past year by +12.87%.
Is H4Z3 a buy, sell or hold?
What are the forecasts/targets for the H4Z3 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 13.5 | 6.7% |
H4Z3 Fundamental Data Overview December 11, 2025
Market Cap EUR = 2.64b (2.64b EUR * 1.0 EUR.EUR)
Beta = 0.0
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 2.64b EUR (2.64b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 2.64b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 2.64b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.77% (E(2.64b)/V(2.64b) * Re(6.77%) + (debt-free company))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)